GILD
GILEAD SCIENCES, INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$150.11
−0.52%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$150.66
From 52W high−3.65%
Volume15.59M
Market cap$186.13B
P/E (TTM)—
P/S (TTM)6.1x
Div yield1.64%
Key dataSep 18, 2026
Open
$150.66
From 52W high
−3.65%
Volume
15.59M
Market cap
$186.13B
ValuationView details →
P/E (Fwd)
16.6x
EV/EBITDA
328.8x
P/E (TTM)
—
RSI (14)
61.6
MomentumView details →
1D Return
−0.52%
YTD Return
+22.35%
SummaryUpdated Jun 1, 2026
Gilead Sciences, Inc. (NASDAQ:GILD) is a leading biopharmaceutical company founded in 1987 and headquartered in Foster City, California. The company went public in 1992 and has established itself as a major player in the pharmaceutical industry, particularly known for its groundbreaking treatments in HIV/AIDS, hepatitis, and oncology. Gilead has built its reputation through innovative drug discovery and development, with a focus on addressing unmet medical needs in serious diseases. The company operates globally, serving patients in the United States, Europe, and international markets through its comprehensive portfolio of specialized medicines.
Similar companies
Latest newsMore news →
Gilead Sciences committed to advancing a technology-transfer process in Brazil aimed at enabling future local production of lenacapavir.4d agoThe Pan American Health Organization (PAHO) announced an agreement with Gilead Sciences to make lenacapavir available for HIV prevention in 14 Latin American and Caribbean countries through its Regional Revolving Funds.4d agoGilead Sciences extended six royalty-free licensing agreements covering 120 countries.4d ago